Daré Bioscience, Inc.
DARE
$2.93
-$0.055-1.84%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 9.80K | 1.88M | 2.84M | 2.82M | 2.81M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.80K | 1.88M | 2.84M | 2.82M | 2.81M |
| Cost of Revenue | 14.31M | 21.65M | 21.65M | 21.65M | 21.64M |
| Gross Profit | -14.30M | -19.76M | -18.81M | -18.83M | -18.83M |
| SG&A Expenses | 9.16M | 10.11M | 10.77M | 11.24M | 11.91M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.46M | 24.92M | 29.59M | 31.20M | 33.55M |
| Operating Income | -23.45M | -23.03M | -26.75M | -28.38M | -30.74M |
| Income Before Tax | -4.05M | -3.60M | -7.20M | -28.87M | -30.16M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.05 | -3.60 | -7.20 | -28.87 | -30.16 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.05M | -3.60M | -7.20M | -28.87M | -30.16M |
| EBIT | -23.45M | -23.03M | -26.75M | -28.38M | -30.74M |
| EBITDA | -23.41M | -22.99M | -26.70M | -28.34M | -30.70M |
| EPS Basic | -0.51 | -0.52 | -1.06 | -3.81 | -4.13 |
| Normalized Basic EPS | -0.37 | -0.31 | -0.64 | -2.36 | -2.57 |
| EPS Diluted | -0.53 | -0.53 | -1.08 | -3.82 | -4.14 |
| Normalized Diluted EPS | -0.37 | -0.31 | -0.65 | -2.36 | -2.57 |
| Average Basic Shares Outstanding | 33.34M | 32.62M | 31.67M | 30.46M | 29.21M |
| Average Diluted Shares Outstanding | 33.41M | 32.68M | 31.74M | 30.46M | 29.21M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |